First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.
Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.
